Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.

Geiger T, Hüsken D, Weiler J, Natt F, Woods-Cook KA, Hall J, Fabbro D.

Anticancer Drug Des. 2000 Dec;15(6):423-30.

PMID:
11716435
2.

Anti-HIV-1 activity in vitro of ceftazidime degradation products.

Hobi R, Hübscher U, Neftel K, Alteri E, Poncioni B, Walker MR, Woods-Cook K, Schneider P, Lazdins JK.

Antivir Chem Chemother. 2001 Mar;12(2):109-18.

PMID:
11527042
3.

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F.

Cancer Res. 2000 Apr 15;60(8):2178-89.

4.

PCTAIRE-1: characterization, subcellular distribution, and cell cycle-dependent kinase activity.

Charrasse S, Carena I, Hagmann J, Woods-Cook K, Ferrari S.

Cell Growth Differ. 1999 Sep;10(9):611-20.

5.
6.

Profile of CGP 61755: a novel and potent HIV-1 protease inhibitor that shows enhanced anti-HIV activity when combined with other antiretroviral agents in vitro.

Lazdins JK, Bold G, Capraro HG, Cozens R, Fässler A, Flesch G, Klimkait T, Lang M, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Walker MR, Woods-Cook K.

Schweiz Med Wochenschr. 1996 Oct 26;126(43):1849-51.

PMID:
8916294
7.

Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2.

Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE.

Mol Cell Biol. 1995 Dec;15(12):6496-505.

8.

The replicative restriction of lymphocytotropic isolates of HIV-1 in macrophages is overcome by TGF-beta.

Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Cerletti N, Shipman R, Bilbe G, McMaster G.

AIDS Res Hum Retroviruses. 1992 Apr;8(4):505-11.

PMID:
1599757
9.

Lack of effect of desferrioxamine on in-vitro HIV-1 replication.

Lazdins JK, Alteri E, Klimkait T, Woods-Cook K, Walker MR, Goutte G, Poncioni B.

Lancet. 1991 Nov 23;338(8778):1341-2. No abstract available.

PMID:
1682729
10.

In vitro effect of transforming growth factor-beta on progression of HIV-1 infection in primary mononuclear phagocytes.

Lazdins JK, Klimkait T, Woods-Cook K, Walker M, Alteri E, Cox D, Cerletti N, Shipman R, Bilbe G, McMaster G.

J Immunol. 1991 Aug 15;147(4):1201-7.

PMID:
1869819
11.

TGF-beta: upregulator of HIV replication in macrophages.

Lazdins JK, Klimkait T, Alteri E, Walker M, Woods-Cook K, Cox D, Bilbe G, Shipman R, Cerletti N, McMaster G.

Res Virol. 1991 Mar-Jun;142(2-3):239-42.

PMID:
1896646
12.

The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages.

Lazdins JK, Woods-Cook K, Walker M, Alteri E.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1157-61.

PMID:
1701314
13.

An assay for the detection of interleukin-1 synthesis inhibitors: effects of antirheumatic drugs.

Rordorf-Adam C, Lazdins J, Woods-Cook K, Alteri E, Henn R, Geiger T, Feige U, Towbin H, Erard F.

Drugs Exp Clin Res. 1989;15(8):355-62.

PMID:
2513175

Supplemental Content

Loading ...
Support Center